CRISPR in Targeted Therapy and Adoptive T Cell Immunotherapy for Hepatocellular Carcinoma

IF 4.2 3区医学 Q2 ONCOLOGY

Journal of Hepatocellular Carcinoma Pub Date : 2024-05-30 DOI:10.2147/jhc.s456683

Fahreddin Palaz, Mehmet Ozsoz, Ali Zarrinpar, Ilyas Sahin

{"title":"CRISPR in Targeted Therapy and Adoptive T Cell Immunotherapy for Hepatocellular Carcinoma","authors":"Fahreddin Palaz, Mehmet Ozsoz, Ali Zarrinpar, Ilyas Sahin","doi":"10.2147/jhc.s456683","DOIUrl":null,"url":null,"abstract":"Abstract: Despite recent therapeutic advancements, outcomes for advanced hepatocellular carcinoma (HCC) remain unsatisfactory, highlighting the need for novel treatments. The CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene-editing technology offers innovative treatment approaches, involving genetic manipulation of either cancer cells or adoptive T cells to combat HCC. This review comprehensively assesses the applications of CRISPR systems in HCC treatment, focusing on in vivo targeting of cancer cells and the development of chimeric antigen receptor (CAR) T cells and T cell receptor (TCR)-engineered T cells. We explore potential synergies between CRISPR-based cancer therapeutics and existing treatment options, discussing ongoing clinical trials and the role of CRISPR technology in improving HCC treatment outcomes with advanced safety measures. In summary, this review provides insights into the promising prospects and current challenges of using CRISPR technology in HCC treatment, with the ultimate goal of improving patient outcomes and revolutionizing the landscape of HCC therapeutics. Keywords: CRISPR, hepatocellular carcinoma, HCC, targeted cancer therapy, adoptive T cell immunotherapy, CAR T cell therapy ","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatocellular Carcinoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/jhc.s456683","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract: Despite recent therapeutic advancements, outcomes for advanced hepatocellular carcinoma (HCC) remain unsatisfactory, highlighting the need for novel treatments. The CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene-editing technology offers innovative treatment approaches, involving genetic manipulation of either cancer cells or adoptive T cells to combat HCC. This review comprehensively assesses the applications of CRISPR systems in HCC treatment, focusing on in vivo targeting of cancer cells and the development of chimeric antigen receptor (CAR) T cells and T cell receptor (TCR)-engineered T cells. We explore potential synergies between CRISPR-based cancer therapeutics and existing treatment options, discussing ongoing clinical trials and the role of CRISPR technology in improving HCC treatment outcomes with advanced safety measures. In summary, this review provides insights into the promising prospects and current challenges of using CRISPR technology in HCC treatment, with the ultimate goal of improving patient outcomes and revolutionizing the landscape of HCC therapeutics.

Keywords: CRISPR, hepatocellular carcinoma, HCC, targeted cancer therapy, adoptive T cell immunotherapy, CAR T cell therapy

查看原文本刊更多论文

CRISPR 在肝细胞癌靶向治疗和适应性 T 细胞免疫疗法中的应用

摘要：尽管最近的治疗取得了进展，但晚期肝细胞癌（HCC）的治疗效果仍不令人满意，这凸显了对新型治疗方法的需求。CRISPR（Clustered Regularly Interspaced Short Palindromic Repeats）基因编辑技术提供了创新的治疗方法，通过对癌细胞或收养性 T 细胞进行基因操作来对抗 HCC。本综述全面评估了CRISPR系统在HCC治疗中的应用，重点关注体内靶向癌细胞以及嵌合抗原受体（CAR）T细胞和T细胞受体（TCR）工程T细胞的开发。我们探讨了基于CRISPR的癌症疗法与现有治疗方案之间的潜在协同作用，讨论了正在进行的临床试验以及CRISPR技术在通过先进的安全措施改善HCC治疗效果方面的作用。总之，本综述深入探讨了在 HCC 治疗中使用 CRISPR 技术的广阔前景和当前挑战，其最终目标是改善患者预后并彻底改变 HCC 治疗方法的面貌：CRISPR；肝细胞癌；HCC；癌症靶向治疗；领养 T 细胞免疫疗法；CAR T 细胞疗法

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊